Compare Lithium Americas Corp (LAC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs Neurocrine Biosciences Inc — how do they compare? Lithium Americas Corp trades at $3.03 (market cap $1.01B), while Neurocrine Biosciences Inc trades at $177.59 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is far larger — about 17.2× Lithium Americas Corp's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals.
| LAC | NBIX | |
|---|---|---|
Market Cap | $1.01B | $17.40B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $180.55 |
52-Week Low | $2.55 | $123.10 |
Enterprise Value | $1.13B | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.90, down 1.69% amid bearish technical signals despite recent earnings beats. The company shows negative profitability with ROE at -11.35% and net income of -$122.09M for 2025, though it maintains strong financing cash flow of $1.14B. Construction milestones at Thacker Pass project progress, with 2026 expected to be pivotal for operational developments according to company guidance.
Investment outlook balances significant project potential against substantial execution risks. While analyst consensus leans positive with 47% buy ratings and no sell recommendations, the stock faces headwinds from negative cash flow from operations and high capital expenditure requirements. Key risks include dilution from share issuances and sensitivity to lithium market dynamics.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% with strong bullish momentum. Recent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, underscore robust growth. The stock shows bullish technical signals with support at $170 and resistance at $173. Revenue growth accelerated to $2.86 billion in 2025, with net income margin improving to 21.55% in 2026 projections. Positive news highlights pipeline advancements and the Soleno acquisition.
Outlook remains positive with a consensus price target of $196.08, implying 13% upside. Key opportunities include sustained earnings growth and pipeline expansion, while risks involve clinical trial outcomes and competitive pressures. Institutional sentiment is strongly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
